MSI1 Gene Liver Cancer (Hepatocellular Carcinoma) clinical trials
7 active Liver Cancer (Hepatocellular Carcinoma) trials that test for MSI1 Gene in their eligibility criteria. Describe your situation to see which ones look like a fit.
- A Phase 1 Study of the Safety and Tolerability of CTX-10726
- Cabozantinib Plus Durvalumab With or Without Tremelimumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal Malignancies
- Lactulose to Improve Gut Health in Cancer Patients Receiving Immunotherapy
- Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors
- A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
- Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies
- A Beta-only IL-2 ImmunoTherapY Study
← All Liver Cancer (Hepatocellular Carcinoma) trials
Guides for people searching for a trial
- How your biomarkers decide which trials you qualify forEGFR, HER2, BRAF, PD-L1 and the rest — what they are and why they increasingly gate access.
- Why people get turned down — and what to do nextWhat eligibility criteria are for, what keeps people out, and where to go when the first door closes.
- How to search for a trial without losing your mindWhere to look, what to gather first, and how to read what you find.
- What Phase 1, 2 and 3 actually mean for youWhat each phase is testing, and how to weigh an early-phase trial against a later one.
- 10 questions to ask before you say yesTreatment, time, cost, safety and your rights. Worth bringing to a screening visit.
- You matched with a trial. What happens now?Phone screens, the screening visit, informed consent, and day one.